IL300365A - Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitor - Google Patents
Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitorInfo
- Publication number
- IL300365A IL300365A IL300365A IL30036523A IL300365A IL 300365 A IL300365 A IL 300365A IL 300365 A IL300365 A IL 300365A IL 30036523 A IL30036523 A IL 30036523A IL 300365 A IL300365 A IL 300365A
- Authority
- IL
- Israel
- Prior art keywords
- crystalline
- anhydrate
- compound
- powder diffraction
- ray powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060281P | 2020-08-03 | 2020-08-03 | |
| PCT/US2021/044341 WO2022031701A1 (en) | 2020-08-03 | 2021-08-03 | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300365A true IL300365A (en) | 2023-04-01 |
Family
ID=77640732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300365A IL300365A (en) | 2020-08-03 | 2021-08-03 | Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230286972A1 (https=) |
| EP (1) | EP4188925A1 (https=) |
| JP (1) | JP7789056B2 (https=) |
| KR (1) | KR20230061395A (https=) |
| CN (1) | CN116917284A (https=) |
| AR (1) | AR123132A1 (https=) |
| AU (1) | AU2021322186A1 (https=) |
| BR (1) | BR112023002013A2 (https=) |
| CA (1) | CA3188250A1 (https=) |
| CL (1) | CL2023000327A1 (https=) |
| CO (1) | CO2023002543A2 (https=) |
| CR (1) | CR20230118A (https=) |
| IL (1) | IL300365A (https=) |
| MX (1) | MX2023001469A (https=) |
| PE (1) | PE20231168A1 (https=) |
| TW (1) | TW202220984A (https=) |
| UY (1) | UY39366A (https=) |
| WO (1) | WO2022031701A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2602139B (en) * | 2020-12-18 | 2024-07-24 | Nexeon Ltd | Electroactive materials for metal-ion batteries |
| WO2025184490A1 (en) | 2024-03-01 | 2025-09-04 | Biogen Ma Inc. | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3555087A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
-
2021
- 2021-08-03 WO PCT/US2021/044341 patent/WO2022031701A1/en not_active Ceased
- 2021-08-03 PE PE2023000189A patent/PE20231168A1/es unknown
- 2021-08-03 TW TW110128540A patent/TW202220984A/zh unknown
- 2021-08-03 KR KR1020237007569A patent/KR20230061395A/ko active Pending
- 2021-08-03 CN CN202180066901.9A patent/CN116917284A/zh active Pending
- 2021-08-03 IL IL300365A patent/IL300365A/en unknown
- 2021-08-03 JP JP2023507579A patent/JP7789056B2/ja active Active
- 2021-08-03 BR BR112023002013A patent/BR112023002013A2/pt not_active Application Discontinuation
- 2021-08-03 AU AU2021322186A patent/AU2021322186A1/en active Pending
- 2021-08-03 EP EP21766024.0A patent/EP4188925A1/en active Pending
- 2021-08-03 AR ARP210102157A patent/AR123132A1/es unknown
- 2021-08-03 UY UY0001039366A patent/UY39366A/es unknown
- 2021-08-03 MX MX2023001469A patent/MX2023001469A/es unknown
- 2021-08-03 US US18/019,270 patent/US20230286972A1/en active Pending
- 2021-08-03 CA CA3188250A patent/CA3188250A1/en active Pending
- 2021-08-03 CR CR20230118A patent/CR20230118A/es unknown
-
2023
- 2023-02-01 CL CL2023000327A patent/CL2023000327A1/es unknown
- 2023-03-01 CO CONC2023/0002543A patent/CO2023002543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202220984A (zh) | 2022-06-01 |
| CN116917284A (zh) | 2023-10-20 |
| PE20231168A1 (es) | 2023-07-26 |
| US20230286972A1 (en) | 2023-09-14 |
| AU2021322186A1 (en) | 2023-04-06 |
| BR112023002013A2 (pt) | 2023-05-02 |
| MX2023001469A (es) | 2023-06-16 |
| EP4188925A1 (en) | 2023-06-07 |
| CR20230118A (es) | 2023-06-02 |
| CA3188250A1 (en) | 2022-02-10 |
| CO2023002543A2 (es) | 2023-06-09 |
| JP7789056B2 (ja) | 2025-12-19 |
| UY39366A (es) | 2022-02-25 |
| CL2023000327A1 (es) | 2023-10-06 |
| JP2023536911A (ja) | 2023-08-30 |
| WO2022031701A1 (en) | 2022-02-10 |
| AR123132A1 (es) | 2022-11-02 |
| KR20230061395A (ko) | 2023-05-08 |
| WO2022031701A9 (en) | 2022-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3049141C (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| US5354760A (en) | Crystalline Tiagabine monohydrate, its preparation and use | |
| IL300365A (en) | Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitor | |
| US7718807B2 (en) | Salt of 1,2-dihydropyridine compound | |
| AU2007315833A1 (en) | A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one | |
| TW201742866A (zh) | 一種腎外髓質分泌鉀通道抑制劑的可藥用鹽 | |
| HUP0302135A2 (hu) | A toraszemid új V. polimorf módosulata, eljárás előállítására, alkalmazása nyersanyagként, valamint ilyen módosulatot tartalmazó gyógyászati készítmények | |
| US20240059661A1 (en) | Solid state forms of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof | |
| CA3046304A1 (en) | A free base oxazine derivative in crystalline form | |
| EA049044B1 (ru) | Кристаллические формы ингибитора о-гликопротеин-2-ацетамидо-2-дезокси-3-d-глюкопиранозидазы | |
| KR20030027119A (ko) | 1,3,4-옥사디아졸 유도체의 신규 결정, 그 제조 방법 및그것을 유효 성분으로서 함유하는 약제 | |
| EP3829716B1 (en) | 5-methyl-4-fluoro-thiazol-2-yl compounds | |
| AU2001100436A4 (en) | Amlodipine hemimaleate | |
| HK40063558A (en) | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof | |
| NZ754849B2 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| HUP0302871A2 (hu) | Tiazolidindion és polimorf módosulatai új sója, eljárás előállítására, ezeket tartalmazó diabetes elleni szerek | |
| SI21121A (sl) | Prosta baza amlodipina | |
| JPWO1995001352A1 (ja) | チアゾリジン誘導体及びそれを含有する医薬 | |
| SI21067A2 (sl) | Amlodipin hemimaleat |